Results from this trial for sarcomatoid renal cell carcinoma (RCC) patients were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019.

Because there are limited treatment options for this aggressive form of RCC, the trial was designed to verify anecdotal reports of good responders to a combination of gemcitabine and vascular endothelial growth factor (VEGF) inhibitors, such as axitinib.

The results were not as good as everyone had hoped for this very aggressive and rare type of kidney cancer, with an objective response rate of 56%, median progression-free survival of 4.2 months and median overall survival of 8.4 months. However, it is good to see that clinical trials are being run in this rare subgroup of RCC patients to ultimately find a more effective treatment.

Read more in UroToday here

Read more in Practice Update here